These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 28550801)
41. Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P. Goode T; O'Connor T; Hopkins A; Moriarty D; O'Sullivan GC; Collins JK; O'Donoghue D; Baird AW; O'Connell J; Shanahan F J Cell Physiol; 2003 Oct; 197(1):30-41. PubMed ID: 12942538 [TBL] [Abstract][Full Text] [Related]
42. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Matalińska J; Świć A; Lipiński P; Misicka A Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293 [TBL] [Abstract][Full Text] [Related]
43. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059 [TBL] [Abstract][Full Text] [Related]
44. Neurokinin-1 receptor antagonism improves postoperative neurocognitive disorder in mice. Li Z; Luo T; Ning X; Xiong C; Wu A Neurosci Lett; 2018 Nov; 687():189-195. PubMed ID: 30273701 [TBL] [Abstract][Full Text] [Related]
45. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies. Isorna I; González-Moles MÁ; Muñoz M; Esteban F J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053 [TBL] [Abstract][Full Text] [Related]
46. Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Muñoz M; Pérez A; Rosso M; Zamarriego C; Rosso R Melanoma Res; 2004 Jun; 14(3):183-8. PubMed ID: 15179186 [TBL] [Abstract][Full Text] [Related]
47. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. Martinez AN; Burmeister AR; Ramesh G; Doyle-Meyers L; Marriott I; Philipp MT J Neuroinflammation; 2017 Feb; 14(1):37. PubMed ID: 28202084 [TBL] [Abstract][Full Text] [Related]
48. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227 [TBL] [Abstract][Full Text] [Related]
49. Involvement of substance P and the NK-1 receptor in pancreatic cancer. Muñoz M; Coveñas R World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029 [TBL] [Abstract][Full Text] [Related]
50. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734 [TBL] [Abstract][Full Text] [Related]
51. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. Azimi E; Reddy VB; Shade KC; Anthony RM; Talbot S; Pereira PJS; Lerner EA JCI Insight; 2016 Oct; 1(16):e89362. PubMed ID: 27734033 [TBL] [Abstract][Full Text] [Related]
52. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Nizam E; Erin N Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097 [TBL] [Abstract][Full Text] [Related]
53. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy. Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358 [TBL] [Abstract][Full Text] [Related]
54. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. Kast RE J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456 [TBL] [Abstract][Full Text] [Related]
55. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Koon HW; Zhao D; Zhan Y; Moyer MP; Pothoulakis C Proc Natl Acad Sci U S A; 2007 Feb; 104(6):2013-8. PubMed ID: 17264209 [TBL] [Abstract][Full Text] [Related]
56. The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Muñoz M; Rosso M; González-Ortega A; Coveñas R Cancers (Basel); 2010 Apr; 2(2):611-23. PubMed ID: 24281084 [TBL] [Abstract][Full Text] [Related]
58. Involvement of substance P and the NK-1 receptor in cancer progression. Muñoz M; Coveñas R Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301 [TBL] [Abstract][Full Text] [Related]
59. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme. Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062 [TBL] [Abstract][Full Text] [Related]
60. Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P. Burmeister AR; Johnson MB; Chauhan VS; Moerdyk-Schauwecker MJ; Young AD; Cooley ID; Martinez AN; Ramesh G; Philipp MT; Marriott I J Neuroinflammation; 2017 Dec; 14(1):245. PubMed ID: 29237453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]